Why Eikon Therapeutics, Inc.’s (EIKN) Stock Is Up 5.19%
As of Tuesday, November 03, Eikon Therapeutics, Inc.’s EIKN share price has surged by 5.19%, which has investors questioning if this is right time to sell.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Commentary & Analysis
Why Eikon Therapeutics, Inc.’s (EIKN) Stock Is Down 11.43%
As of Monday, October 26, Eikon Therapeutics, Inc.’s EIKN share price has dipped by 11.43%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Eikon Therapeutics, Inc.’s (EIKN) Stock Is Down 12.60%
As of Monday, October 26, Eikon Therapeutics, Inc.’s EIKN share price has dipped by 12.60%, which has investors questioning if this is right time to buy.Omar Beirat
Why Eikon Therapeutics, Inc.’s (EIKN) Stock Is Down 8.62%
As of Friday, October 23, Eikon Therapeutics, Inc.’s EIKN share price has dipped by 8.62%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Eikon Therapeutics, Inc.’s (EIKN) Stock Is Up 6.49%
As of Tuesday, October 20, Eikon Therapeutics, Inc.’s EIKN share price has surged by 6.49%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | EIKN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $319.6 | $219.9 | 33% |
|
| Shares Out (Mil) | 54.1 | 54.1 | 49% |
|
| Institutional Ownership | 89.2% | 92.9% | 57% |
|
| Float (Mil) | 34.8 | 41.4 | 39% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 627 | 522 | 61% |
|
| Price Change (52-week) |
na | 44.7% | na |
|
| Growth | EIKN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 6 | 6 | |
| Current EPS | ($1.604) | ($6.576) | ($6.694) | |
| Month Ago EPS | ($1.575) | ($6.412) | ($6.334) | |
| # Rev Up | 2 | 1 | 0 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | ($1.556) | ($6.349) | ($6.185) | |
| Year/Year Chg | (1.8%) | (94.3%) | (95.0%) | |
| Financials | EIKN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($322) | ($44) | 4% |
|
| EPS (TTM) | ($13.722) | ($1.500) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($256) | ($35) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($30) | $0 | 24% |
|
| Long-Term Debt (Q1) (Mil) | $243 | $4 | 52% |
|
| Enterprise Value (Q1) (Mil) | $338 | $166 | 31% |
|
| Valuation | EIKN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.68 | 2.06 | 15% |
|
| P/E | na | 16.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | EIKN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (61.0%) | na |
|
| ROA | (82.7%) | (47.5%) | 7% |
|
| ROE | 611.1% | (52.7%) | 100% |
|
| Liabilities to Assets | 40.2% | 29.6% | 31% |
|
| F-Score | 1 | 3 | na |
|
Eikon Therapeutics, Inc. did not pass any screens on 11/6/2026.
